Clinical decision-making for cardiovascular disease risk should prioritize comprehensive metabolic health over isolated biomarker values.

Study: Cardiovascular risk assessment tools are insufficient for patients with metabolic dysfunction associated steatotic liver disease.

Doctors usually use simple blood tests to guess heart disease risk, but this study found those tests often get it wrong for people with fatty liver disease. That means doctors need to look at the whole picture of a person’s metabolism, not just one number.

Study: Improving cardiovascular risk prediction in metabolic liver disease with a novel biomarker-enhanced model

Doctors usually check a few blood numbers to guess heart attack risk, but this study shows that adding info about liver health makes their predictions much better. So, looking at the whole metabolic picture works better than just one number.

Study: OP04 The Modernized Cardiff Model: Multifaceted Modeling In The Era Of Cardiovascular-Kidney-Metabolic Syndrome

Doctors who look at a patient’s overall health—like heart and kidney risk, not just blood sugar—make better decisions that save lives and money. The study shows this approach works better than focusing on one number alone.

Study: Fuzzy logic based risk assessment system giving individualized advice for metabolic syndrome and fatal cardiovascular diseases

This study built a computer tool that looks at many health factors together—like waist size, blood pressure, and sugar levels—to guess heart disease risk, and it got it right 93 out of 100 times. That’s better than just checking one number, so it supports the idea that doctors should look at the whole picture, not just one blood test.